WO2004103380A1 - 水可溶性イソフラボン組成物およびその製造方法並びにその用途 - Google Patents
水可溶性イソフラボン組成物およびその製造方法並びにその用途 Download PDFInfo
- Publication number
- WO2004103380A1 WO2004103380A1 PCT/JP2004/006726 JP2004006726W WO2004103380A1 WO 2004103380 A1 WO2004103380 A1 WO 2004103380A1 JP 2004006726 W JP2004006726 W JP 2004006726W WO 2004103380 A1 WO2004103380 A1 WO 2004103380A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- isoflavone
- aglycone
- water
- composition
- soluble
- Prior art date
Links
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims abstract description 334
- 235000008696 isoflavones Nutrition 0.000 title claims abstract description 334
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 title claims abstract description 292
- 239000000203 mixture Substances 0.000 title claims abstract description 145
- 238000000034 method Methods 0.000 title claims description 21
- 230000008569 process Effects 0.000 title description 3
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims abstract description 106
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims abstract description 106
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims abstract description 106
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000002537 cosmetic Substances 0.000 claims abstract description 18
- 235000013361 beverage Nutrition 0.000 claims abstract description 14
- 108090000790 Enzymes Proteins 0.000 claims description 74
- 102000004190 Enzymes Human genes 0.000 claims description 74
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 63
- 229920000858 Cyclodextrin Polymers 0.000 claims description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 235000013305 food Nutrition 0.000 claims description 35
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 33
- 229930012930 isoflavone derivative Natural products 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 21
- 235000003687 soy isoflavones Nutrition 0.000 claims description 18
- 235000000346 sugar Nutrition 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 14
- 239000002244 precipitate Substances 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 10
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 9
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 9
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 9
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 9
- 229940025878 hesperidin Drugs 0.000 claims description 9
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 9
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 9
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- 239000003513 alkali Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 108700023372 Glycosyltransferases Proteins 0.000 claims description 7
- 102000051366 Glycosyltransferases Human genes 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 6
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 6
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 6
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 6
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 6
- 235000005493 rutin Nutrition 0.000 claims description 6
- 229960004555 rutoside Drugs 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- FAPIALUGWUHNOC-VPRICQMDSA-N 3-phenyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1C1=C(C=2C=CC=CC=2)C(=O)C2=CC=CC=C2O1 FAPIALUGWUHNOC-VPRICQMDSA-N 0.000 abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 83
- 230000000694 effects Effects 0.000 description 25
- 239000000047 product Substances 0.000 description 20
- 235000010469 Glycine max Nutrition 0.000 description 18
- 244000068988 Glycine max Species 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 230000037182 bone density Effects 0.000 description 17
- 208000001132 Osteoporosis Diseases 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 10
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 235000006539 genistein Nutrition 0.000 description 9
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 9
- 229940045109 genistein Drugs 0.000 description 9
- 235000013402 health food Nutrition 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 239000012535 impurity Substances 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 235000016127 added sugars Nutrition 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 235000005979 Citrus limon Nutrition 0.000 description 6
- 244000131522 Citrus pyriformis Species 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 6
- 229960004853 betadex Drugs 0.000 description 6
- 230000004097 bone metabolism Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 235000001727 glucose Nutrition 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 239000001116 FEMA 4028 Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 235000007240 daidzein Nutrition 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 235000015110 jellies Nutrition 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 244000228451 Stevia rebaudiana Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 229960005069 calcium Drugs 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 229940097362 cyclodextrins Drugs 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 235000015205 orange juice Nutrition 0.000 description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 4
- 235000014214 soft drink Nutrition 0.000 description 4
- 235000020712 soy bean extract Nutrition 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 235000016795 Cola Nutrition 0.000 description 2
- 235000011824 Cola pachycarpa Nutrition 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 150000002304 glucoses Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000009474 immediate action Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241001634499 Cola Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000178960 Paenibacillus macerans Species 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 102000020006 aldose 1-epimerase Human genes 0.000 description 1
- 108091022872 aldose 1-epimerase Proteins 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- -1 isoflavone compound Chemical class 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013997 pineapple juice Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000006098 transglycosylation Effects 0.000 description 1
- 238000005918 transglycosylation reaction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a water-soluble isoflavone composition, a method for producing the same, and uses thereof.
- the present invention relates to a water-soluble isoflavone composition, a method for producing the same, and its use, and more particularly, to a water-soluble isoflavone composition, which is excellent in water solubility, has an immediate effect in absorption, and has excellent pharmacological action after absorption.
- the present invention relates to a water-soluble isoflavone composition, a method for producing the same, and uses thereof.
- Isoflavones and their derivatives have the effect of preventing the excessive outflow of calcium from bones and preventing the replenishment of calcium, preventing osteoporosis, which is common in the elderly, and reducing the imbalance of female hormones. It is known to be effective in alleviating and supplementing the role of female hormones, preventing menopause, preventing cholesterol oxidation and preventing arteriosclerosis, and preventing adult diseases such as hyperlipidemia. I have. Therefore, intake of soy isoflavone and its derivatives is recommended, and various methods for extracting soy isoflavone and its derivatives have been proposed.
- osteoporosis drug administration of a calcium preparation, an active vitamin D preparation, a female hormone preparation, or the like has hitherto been mentioned. Also, the development of osteoporosis
- the present inventors have proposed a method for extracting a soybean isoflavone derivative or a method for improving its water solubility, which has been conventionally proposed, and a method obtained therefrom. I studied hard.
- Examples of a method for extracting a soybean isoflavone derivative or a method for improving the water solubility thereof include, for example, contacting a soybean extract with a synthetic adsorption resin to adsorb isoflavone on the resin, and then using an organic solvent or an organic solvent.
- a method of eluting isoflavones with a mixture of a solvent and water JP-A-62-126186: Patent Document 1)
- a method for producing a water-soluble isoflavone derivative extract comprising heating and dissolving a soybean-derived isoflavone derivative extract in an ethanol solution in the presence of branched maltosyl spike cyclodextrin, and removing insoluble materials after cooling (Japanese Patent Application Laid-Open 2002-155072 Publication: Patent Document 3)
- a method for producing a water-soluble soy isoflavone which comprises mixing a crude extract obtained from a soybean material with cyclodextrin in an aqueous solution and then removing insolubles (JP-A-10-298175) Information: Patent Document 4),
- an isoflavone derivative is encapsulated with ⁇ - or ⁇ -cyclodextrin, which suppresses bitterness, etc., has high solubility in water, and has high absorption efficiency in the body (Tokuhei Hei 9 Japanese Patent No. 309902: Patent Document 5) has also been proposed.
- the extract obtained by the method described in JP-A-62-126186 and JP-A-11-263786 is also described in JP-A-2002-155072. Poor solubility in aqueous solution, as described.
- the clathrate described in JP-A-9-309902 has room for improvement in solubility in aqueous solution and stability in aqueous solution.
- an isoflavone derivative extract can be efficiently recovered.
- the isoflavone or its derivative may be further refined in terms of the yield of isoflavone or a derivative thereof since the product is also collected in the filtrate. If ⁇ -Dalcosinole is used in the presence of glycosyltransferase and ethanol is used, the ethanol contained in the enzyme inhibits the enzyme activity, so it is necessary to volatilize and remove ethanol prior to enzyme treatment.
- Patent Document 6 discloses that an isoflavone derivative is extracted with an alkaline solution of soybean and / or soybean food product ⁇ 8 or more, or with hot water or an organic solvent. The isoflavone derivative is extracted, and then the glycoglycosyl sugar compound is reacted with a glycosyltransferase to produce a hyperglycosyl isoflavone derivative. The acid is then reduced to 5.5 or less or cooled to remove impurities as a precipitate. A method for producing a derived isoflavone derivative or its aglycone is described.
- the obtained soybean-derived polydarcosyl isoflavone derivative contains soybean impurities other than isoflavone and its derivative, and contains an alkali side. Originated from impurities due to the enzymatic reaction The color value was high and the decomposition reaction occurred, so there was room for improvement immediately.
- Patent Document 1 JP-A-62-126186
- Patent Document 2 Japanese Patent Application Laid-Open No. 11-263786
- Patent Document 3 Japanese Patent Application Laid-Open No. 2002-155072
- Patent Document 4 JP-A-10-298175
- Patent Document 5 Japanese Patent Application Laid-Open No. 9-309902
- Patent Document 6 JP-A-2000-327691
- the present invention is capable of rapidly absorbing into the body and stopping at a high concentration in the body for a longer period of time, and is expected to have effects such as improvement of bone density, prevention and treatment of osteoporosis, and the like.
- Enzyme-treated isoflavones that can be used as pharmaceuticals such as density enhancers and can be added to general foods, drinks, health foods, functional foods or feeds to improve bone metabolism in a balanced and efficient manner It is intended to provide a similar composition (isoflavone derivative composition).
- An object of the present invention is to provide a suitable use of a water-soluble isoflavone composition, such as a cosmetic product, which has the properties of the water-soluble isoflavone composition.
- the present invention provides a method for producing an enzyme-treated isoflavone, which is capable of producing an enzyme-treated isoflavone in high yield using a soybean isoflavone extract containing soy isoflavones as a raw material. It is an object.
- the present inventors have conducted intensive studies and, as a result, surprisingly, when a flavonoid having a specific composition ratio is ingested, the body is maintained for a longer period of time than when a conventional flavonoid is ingested.
- the flavonoids having the above specific composition ratio can be used as pharmaceuticals such as bone density improvers, and can be used as medicines for improving bone density and preventing or treating osteoporosis.
- the present inventors have found that the use of the compound in foods, functional foods and feeds can improve bone metabolism in a well-balanced and efficient manner, and have completed the present invention.
- the present invention relates to the following matters.
- the ratio is preferably 5/1 or more.
- the water-soluble isoflavone composition according to the present invention is an isoflavone composition comprising ⁇ -gnorecosyl isoflavone, isoflavone and isoflavone aglycone, wherein the amount of isoflavone aglycone in the composition is such that It is characterized by 0.01 to 20% of the total amount of aglycone in the composition.
- the ⁇ -darcosyl isoflavone is preferably a mixture of isoflavone and an average of 2.0 to 20 glucose added by ⁇ -bond to isoflavone.
- the isoflavone composition preferably contains hedarcosyl isoflavone, isoflavone, and isoflavone aglycone.
- the composition is obtained by allowing cyclodextrin and glycosyltransferase to act on a composition containing the above-mentioned isoflavone and isoflavone derivatives.
- cyclodextrin is allowed to act on a composition containing the above-mentioned darcosyl isoflavone power isoflavone and isoflavone derivative,
- the precipitate is obtained by filtering and removing a precipitate generated by cooling and then reacting with a glycosyltransferase.
- the cyclodextrin is ⁇ -cyclodextrin or branched ⁇ -cyclodextrin since a water-soluble substance having good water solubility can be obtained.
- a food, drink, cosmetic, medicine or feed according to the present invention is characterized by containing the water-soluble isoflavone composition described in any of the above.
- the food or drink is preferably an acidic beverage.
- the food or drink may further contain enzyme-treated hesperidin and / or enzyme-treated rutin.
- the soy isoflavone extract is suspended in water or an aqueous medium, cyclodextrin is added to the obtained suspension, and the suspension is heated to 40 to 100 ° C to dissolve the cyclodextrin.
- the resulting solution was mixed with an alkali to adjust the pH to 8-13 to dissolve the isoflavones, and the isoflavones were included in cyclodextrin.
- the present invention it is rapidly absorbed into the body, has an immediate effect, and can stay at a high concentration in the body for a longer period of time, has a sustained effect, improves bone density, It can be expected to have better effects such as osteoporosis prevention and treatment, can be used as a drug such as a bone density improver, and can be used by adding it to general food, drink, health food, functional food or feed.
- a water-soluble isoflavone composition enzyme-treated isoflavone composition
- foods, beverages, cosmetics, pharmaceuticals, feeds, and the like which are uses that make full use of the properties of the water-soluble isoflavone composition.
- isoflavone in producing enzyme-treated isoflavones using (crude) soy isoflavone extract as a raw material, isoflavone is obtained from crude soy isoflavone extract by using an alkali without depending on ethanol dissolution. Dissolving, extracting, etc., eliminates the need for an ethanol removal step prior to isoflavone enzymatic treatment.
- water-soluble isoflavone composition according to the present invention, a method for producing the same, and uses thereof will be specifically described.
- the water-soluble isoflavone composition according to the present invention comprises ⁇ -gnorecosyl isoflavone, isoflavone, and, if necessary, isoflavone aglycone;
- Ratio of the amount of aglycone contained in the sum of isoflavone and isoflavone aglycone to the amount of aglycone in the darcosyl isoflavone (Cg) [aglycone amount in the darcosyl isoflavone Z (aglycone in the isoflavone) Amount + isoflavone aglycone)], 2.5 / 1 or more is desirable from the viewpoint of stability in aqueous solution, immediate effect upon absorption when taken orally, and sustainability of the drug effect after absorption.
- the aglycone amount ratio may be either a weight ratio or a molar ratio, but is indicated by a weight ratio unless otherwise specified.
- the amounts of aglycone in polygnorecosyl isoflavone, the amount of aglycone in isoflavone, the amount of aglycone in isoflavone aglycone, etc. are all converted to genistein. Ask for it.
- the upper limit of the aglycone amount ratio (Cg) is usually 25/1 or less, which means that the composition is rapidly absorbed into the body, has immediate effect, and has a long-term effect. It can stop at a high concentration throughout the body and has a long-lasting effect, can be expected to have better effects such as improvement of bone density, prevention of osteoporosis, etc., and can be used as a drug such as a bone density improver, In addition, it can be used by adding it to general food, drink, health food, functional food or feed. It is desirable because bone metabolism can be efficiently improved in a well-balanced manner.
- the aglycone content ratio (Cg) (weight ratio) in the isoflavone composition is less than 2.5 / 1, the solution stability of the composition is reduced, and therefore, especially in liquids such as beverages. Not suitable for use inside.
- the number of glucose (G) bonded to isoflavone is 2.0 to 20 on average in the above-mentioned dalcosyl isoflavone. Glycon is desirable because it can maintain stability in an aqueous solution.
- the above isoflavone composition according to the present invention contains hair darcosyl isoflavone and isoflavone as essential components.
- hair darcosyl isoflavone, isoflavone, and isoflavone are included.
- Aglycone is included in the above-mentioned effects, that is, it is rapidly absorbed into the body and has a strong immediate effect, and can be stopped at a high concentration in the body for a longer period of time, so that the effect is more sustained. It can be expected to have better effects such as improvement of bone density, prevention and treatment of osteoporosis, and can be used as a medicine such as bone density improver, and it can be used for general food and drink, health food, functional food or feed. It is desirable to use it with a supplemental caroline because it can improve bone metabolism in a balanced and efficient manner.
- dextrins including cyclodextrins (CD)
- oligosaccharides in addition to the ⁇ -darcosyl isoflavone, isoflavone, and isoflavone aglycone optionally contained, are included.
- Such saccharides, proteins, peptides, other flavonoids, and the like may be contained within a range not inconsistent with the object of the present invention.
- the isoflavone glycone has the following formula [1]:
- the group has a structure in which the group R 3 is H. (In the formula [I], the definitions of R 1 , R 2 , and R 3 are as shown in Table 1 above.)
- the number of added sugars (number of added glucoses) ( ⁇ ) of ⁇ -gnorecosyl isoflavone that is, a case where the compound of the above formula [I] is composed of a plurality of glucoses connected by an R 3 power bond is used.
- the average number of gnorecoses added by the heat bond is 2.0 or more. Improvement of water solubility of the isoflavone composition of the present invention, It is desirable from the viewpoint of maintaining the stability of the soflavona glycol in an aqueous solution.
- the upper limit of the number of added sugars ( ⁇ ) of ⁇ _darcosyl isoflavone is not particularly limited, but is usually up to about 20.
- the cyclohextrin is reacted with a composition containing isoflavone and an isoflavone derivative, and then cooled under acidic conditions, as described below.
- P H5. 0- 7. 0 is obtained by the action of glycosyltransferase, degradation of isoflavones and isoflavone derivatives This is preferable because ⁇ -darcosyl isoflavone and a composition thereof are obtained with almost no occurrence and a good yield.
- the cyclodextrin includes ⁇ -type, ⁇ -type, and ⁇ -type.
- -cyclodextrin or branched -cyclodextrin is preferable in the production of the composition, since it efficiently includes and stabilizes isoflavone.
- the water-soluble isoflavone composition according to the present invention is an isoflavone composition containing hegnolecosyl isoflavone, isoflavone and isoflavone aglycone, and the amount of isoflavone aglycone in the composition.
- the amount is preferably 0.01% to 20% of the total amount of aglycone in the product, and more preferably 0.5% to 10.0%.
- a water-soluble isoflavone composition containing isoflavone aglycone in such an amount tends to be particularly excellent in immediate effect and sustainability.
- the isoflavone aglycone content is particularly less than 0.01%, there is a tendency for lack of immediate effect, and when it exceeds 20%, precipitation occurs in the solution. It tends to be sloppy.
- the food, drink, cosmetics, medicine, or feed (collectively, also referred to as “food, etc.”) according to the present invention is characterized by containing the water-soluble isoflavone composition described above.
- the water-soluble isoflavone composition contained in the food and drink is excellent in water solubility, for example, it can be dissolved in 1 liter of water at 5 ° C in an amount of lg, and the taste is good.
- the water-soluble isoflavone composition contained in the food or drink may be water or natural juice.
- Coffee oolong tea, black tea, barley tea, green tea, cola, ramune, cider, milk cocoa, cocoa and other soft drinks, processed milk, fermented milk, dairy products, lactic acid bacteria drinks and other aqueous drinks; miso, soy sauce, soba soup, mentsuyu Liquid or semi-solid seasonings such as grilled meat sauce, broth, sauce, ketchup, mayonnaise, dressing;
- Aqueous confectionery such as jelly and pudding
- solubility in, for example, and the amount thereof is not particularly limited, and can be appropriately set according to the type of food or drink.
- these foods and drinks are particularly excellent in solubility in acidic beverages.
- acidic beverages such as citrus juice, apple juice, tomato juice, pineapple juice, cola, lactic acid bacteria beverage, etc.
- it is used in an amount of 001-10 g.
- Such a food or drink, or cosmetics, medicine or feed may further contain enzyme-treated hesperidin and / or enzyme-treated noretin at an optional ratio to the water-soluble isoflavone composition.
- the food and drink containing the enzyme-treated hesperidin and the water-soluble isoflavone composition or the enzyme-treated hesperidin and the enzyme-treated norretin and the water-soluble isoflavone composition are excellent in preventing and improving osteoporosis and improving cardiovascular disease. I have.
- the water-soluble isoflavone composition according to the present invention when taken orally, has an immediate effect of being rapidly absorbed into the body, and can remain at a high concentration in the body for a longer period of time, so that the effect can be maintained. It can be expected to have better effects such as improvement of bone density, prevention and treatment of osteoporosis, etc., and improvement of bone density, prevention of osteoporosis ⁇ therapeutic agent, prevention of menopause ⁇ therapeutic agent, cancer It can be used as a drug such as a cell growth inhibitor.
- the water-soluble isoflavone composition is further added to general foods and drinks, health foods, functional foods, luxury goods, feeds, quasi-drugs and the like in an optional amount to improve bone metabolism and the like.
- the balance can be efficiently achieved.
- Examples of general foods and drinks include, more specifically, confectionery, western confectionery, frozen confectionery, syrup, processed fruit products, processed vegetable products, pickles, fish meat, ham, sausage, canned food, bottled products, alcoholic beverages, and the like;
- luxury products include tobacco, gum, etc .
- feeds include livestock, poultry, fish, pets and other feeds, feeds, etc .
- dani cosmetics include lipsticks, lip balms, lotions, emulsions, creams, etc. Hair dressing and the like;
- Examples of quasi-drugs include toothpaste.
- the water-soluble isoflavone composition of the present invention may be used as an oral preparation, an external preparation, or a medicinal preparation for the above-mentioned use, or may be used as an additive for various foods, cosmetics, and feeds.
- the water-soluble isoflavone composition according to the present invention comprises crude soybean germ, soybean flour, defatted soybean, kinako, soymilk, soybean, etc., containing soy isoflavones in an amount of 0.05 to 0.35% (% by weight).
- soybean extract (crude soybean kaugee product)
- a soybean isoflavone extract containing 590% of isoflavones is used, and the soybean isoflavone extract is first added to water or aqueous medium per liter.
- the amount of cyclodextrin used is 0.1 to 4000 g, preferably 1 to 2000 g, per 1 liter of the suspension.
- alkali examples include KOH, NaOH, and sodium hydrogen carbonate.
- a solution containing isoflavones included in cyclodextrin is adjusted to pH 5.5-2.0, preferably pH 4.5-3.0 by adding and mixing an acid.
- the temperature is lowered to 60 ° C, preferably 13-20 ° C, to cause precipitation.
- the acid include acetic acid, hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, citric acid, which can be an organic acid or an inorganic acid.
- the resulting precipitate is removed by filtration, and further subjected to an enzyme treatment as described below to prepare a water-soluble isoflavone composition.
- the filtrate obtained by removing the precipitate by filtration as described above is subjected to pH 5.0 to 9.0, preferably pH 5.0, which is a condition having good enzyme activity. Adjust to 5-7.0, and perform enzyme treatment in the usual way.
- the cyclodextrin-derived sugar is transferred to the isoflavones.
- This sugar is usually obtained by enclosing isoflavones and using a part (or all) of cyclodextrin.
- starch, partially decomposed products, and sugar are added. This may be used for sugar transfer.
- the enzyme is not particularly limited as long as it is an enzyme capable of transglycosylation to isoflavones.
- a cyclodextrin glucanotransferase derived from a microorganism belonging to the genus Bacillus such as Bacillus stearothermophilus or Bacillus macerans is used.
- CGTase can be preferably used, and CGTase derived from Bacillus stearothermophilus is more preferred because of its high sugar transfer efficiency.
- CGTases derived from microorganisms belonging to the same genus Bacillus such as Bacillus 'megaterium, Bacillus' circulans can also be used.
- two or more enzymes may be used in combination.
- the amount of the enzyme used and the conditions for the enzyme treatment may be determined according to a conventional method.
- the water-soluble isoflavone composition thus treated with the enzyme has the same physiological activity as the isoflavones before the enzyme treatment, and is extremely superior to the untreated product in terms of water solubility. You.
- the water-soluble isoflavone composition treated with the enzyme may be a non-polar porous material previously activated with a water-containing organic solvent such as 10-99.5% (wt%) ethanol or an organic solvent.
- a water-containing organic solvent such as 10-99.5% (wt%) ethanol or an organic solvent.
- the isoflavones may be eluted, the eluate may be collected, and the solvent may be distilled off, followed by lyophilization or the like.
- the “total isoflavone content” (the definition will be described later) of the enzyme-treated isoflavones can be generally increased to about 2080%.
- the porous adsorption resin those described in JP-A-2000-327691, page 4, column [0009], for example, "Diaion HP”, “Duolite S”, “Amberlite XAD” and the like are used. do it.
- the total isoflavone content may be increased by chromatographic separation.
- the total isoflavone content in this water-soluble isoflavone composition is usually 5 to 90%, preferably 20 to 40% to maintain the ratio (Cg) in a preferable range. Desirable.
- ethanol is not used for dissolving the isoflavones to be subjected to the enzymatic reaction. Therefore, prior to the subsequent enzymatic treatment, ethanol, which inhibits the enzymatic activity, is used. The removal step can be made unnecessary. As a result, a water-soluble isoflavone composition can be efficiently produced with fewer steps and fewer steps.
- ethanol is not used in the step of producing a water-soluble isoflavone composition using a soy isoflavone extract (extract), and therefore, ethanol-soluble is contained in the extract.
- extract soy isoflavone extract
- the present invention provides a method for producing a water-soluble isoflavone composition, which can produce a hegnolecosyl isoflavone at a high yield without inflow of impurities.
- the average number of added sugars (n) of the sugarcane isoflavone contained in the composition is 2.0 or more.
- the water-soluble isoflavone composition obtained as described above is used as it is so that the aglycone content ratio (Cg) in the isoflavone composition becomes 2.5 / 1 or more.
- Cg aglycone content ratio
- the upper limit of the aglycone ratio (Cg) is not particularly limited, but is usually about 25/1.
- the water-soluble isoflavone composition according to the present invention is an isoflavone composition containing dalcosyl isoflavone, isoflavone, and isoflavone aglycone, wherein the isoflavone aglycone in the composition is As described above, it is preferable that the amount is 0.01% to 20% of the total amount of aglycone in the composition. However, in order to adjust the amount of isoflavone aglycone in this manner, for example, it is preferable to use an enzyme-treated isoflavone.
- the known isoflavone aglycone may be added to a predetermined amount based on the amount of the aglycone contained in the phenolic isolefosyl isoflavone and isoflavone contained in the mixture, and the mixture may be alkali-dissolved and then adjusted to a desired pH.
- the total isoflavone content (meaning the sum of the isoflavone content (unit: wt%)) is the enzyme-treated isoflavone which hydrolyzes the sugar attached to isoflavone by the action of glycosyltransferase (CGTase). Remove with Gunole Coamylase) and measure.
- CCTase glycosyltransferase
- the enzyme-treated isoflavone lg of the sample was dissolved in 0.1 litter of water at 25 ° C, and gnorecoamylase was added at 0.1 Olg, and then ⁇ 5.0 at a temperature of 50 ° C.
- gnorecoamylase was added at 0.1 Olg, and then ⁇ 5.0 at a temperature of 50 ° C.
- the adsorbed fraction is desorbed with 150 ml of 60% ethanol, the alcohol is distilled off, and then dalcoamylase is added with 0.1 Olg, and the mixture is allowed to act at pH 5.0 and a temperature of 50 ° C for 5 hours.
- the total amount of isoflavone in the enzyme-treated isoflavone obtained by the above-described method for measuring the total isoflavone content is converted into genistin, and the number of moles thereof is obtained (E).
- Sample A Dissolve 0.05 g in 100 ml of ion-exchanged water at 25 ° C and measure under the same HPLC conditions as described in the section on measuring the total isoflavone content. Based on the “Test Methods for Soy Isoflavones” in the Health Supplement Standards Standards Collection issued by the Japan Health 'Nutrition Food Association, the isoflavones (F) and isoflavone aglycones (G) in the samples were used as the soy-in standard. Using the quasi product, determine the amount of aglycone as genistein. That is, the amount of aglycone is a value obtained by converting to genistein.
- the total isoflavone in the sample was measured as genistein, and the value obtained by subtracting the above (F) and (G) was used as the value of the darcosyl isoflavone. Aglycone amount.
- the soy isoflavone extract 3g containing isoflavones was suspended in I-exchanged water 600ml in an amount of 40% (wt 0/0). Next, 27 g of j3-cyclodextrin was added to the obtained suspension, and the mixture was heated to 70 ° C. to dissolve j3-cyclodextrin. To this solution, 9 ml of a 15% aqueous sodium hydroxide solution was added and mixed, and the mixture was adjusted to pH 11 to completely dissolve the isoflavone, and the isoflavone was included in ⁇ -cyclodextrin.
- the obtained filtrate was adjusted to pH 5.5 with 1 ml of a 15% sodium hydroxide solution.
- reaction solution was heated at a temperature of 90 ° C or higher for 1 hour to inactivate the enzyme. Then, filtration was performed. The collected filtrate was concentrated and freeze-dried to obtain 27.6 g of a dried product.
- the “total isoflavone content” in the dried product was 4.02%.
- an aqueous solution (concentration: 5.5% by weight) of the above dried product was added to a nonpolar porous adsorption resin (manufactured by Organo Co., Ltd., model number: XAD-7), which had been activated by passing 50% ethanol through in advance. ) After passing 500 ml of the solution to adsorb the isoflavones to the resin, the resin was washed with 1000 ml of flowing water to remove cyclodextrin (CD) and CD degradation products. Thereafter, 50% ethanol was passed through to elute the adsorbed isoflavones. Collect the distillate containing isoflavones, distill off the alcohol in the distillate, freeze-dry and solid 3. 5 g were obtained.
- a nonpolar porous adsorption resin manufactured by Organo Co., Ltd., model number: XAD-7
- Example A This product (water-soluble isoflavone composition) had a total isoflavone content of 35.8% (this is referred to as “Sample A”).
- ⁇ -gnorecosyl isoflavone (as isoflavone) was 29.2% (18.3% as aglycone), 6.6% isoflavone (4.1% as aglycone) and 0% isoflavone aglycone. , 3.6.
- soy isoflavone extract having a total isoflavone content of 40%
- 38 ml of an aqueous solution of ethanol having a concentration of about 30% was added and mixed, and then j3-cyclodextrin was used in an amount 9 times that of the soy isoflavone extract.
- the mixture was heated to 60 ° C. with stirring, kept at that temperature for 30 minutes, and the isoflavones were included in ⁇ -cyclodextrin.
- sample B a solid (based on JP-A-2002-155072) (referred to as sample B).
- Example 1 of the present invention 1.2 g of the soy isoflavone extract was dissolved at a pH of 8 or more, and the solution was covered with 10.8 g of / 3_cyclodextrin, returned to the acidic range, and filtered.
- HPLC High Performance Liquid Chromatography I
- the total isoflavone content of sample C of the present invention was 3.85% compared to the total isoflavone content of sample B in which 30% ethanol was used as a solvent.
- the total isoflavone content is high at 4.12%. The reason is that in sample ⁇ , the ethanol-soluble impurities of the soy isoflavone extract flow out into the filtrate and are collected, but in sample C, ethanol is not used during the preparation, so that contamination of the filtrate into impurities is suppressed. It seems that the total isoflavone content was increased.
- Example 1 of the present invention the isoflavone was dissolved at ⁇ 8 or more, and the solution was included with cyclodextrin, and then ⁇ was adjusted to the neutral region.Therefore, there was no need to distill ethanol. Since it is possible to proceed to the enzymatic reaction as it is, there is an advantage that the step of the enzymatic treatment reaction can be simplified.
- Rats should be kept at room temperature 22 ⁇ 3 ° C, relative humidity 50 ⁇ 20%, ventilation rate 10 times / hour (all fresh air method), lighting 12 hours / day (from 6:00 am to 6:00 pm) In a breeding room set to 150-300 lux (lighting, 150-300 lux), one rat cage was housed per stainless steel rat cage and housed.
- a purified feed (solid feed containing AIN-76A, manufactured by Oriental Yeast Co., Ltd.) was fed from a feeder attached to a cage, and the feed was freely taken from the time of arrival.
- drinking water was supplied from a private tap water via a polycarbonate water bottle and allowed to freely ingest.
- the groups were divided into three groups of 9 animals by healthy stratification by weight stratification, and the average weight of each group was as equal as possible. . On the day of administration, the rats were 6 weeks old and weighed 137 179 g.
- (V) Group composition is as follows: Enzyme-treated isoflavone administration group, isoflavone aglycone administration group, darcosyl isoflavone / (isoflavone + isoflavone aglycone) aglycone weight There were three groups consisting of a mixed sample administration group with a ratio of 3.6 / 1.
- Soact W 33.3% isoflavone aglycone, manufactured by Kikkoman Co., Ltd.
- isoflavone aglycone As a test substance, “Soact W” (33.3% isoflavone aglycone, manufactured by Kikkoman Co., Ltd.) was used as the isoflavone aglycone, and the enzyme-treated isoflavone was used as the test substance.
- Example A produced in Example 1 was used.
- Each test substance was suspended or dissolved in a 0.5% sodium carboxymethylcellulose (CMC-Na) aqueous solution.
- the rats were fasted for 18 hours, and were orally administered by gavage to rats at an oral dose of 50 mol per rat body weight. Until 24 hours after administration, blood was collected and urine was collected.
- CMC-Na sodium carboxymethylcellulose
- Injection volume 10 ⁇ l.
- the “water-soluble isoflavone composition” and the “mixture of the water-soluble isoflavone composition and isoflavone aglycone” of the present invention are more effective in blood than the isoflavone aglycone.
- High and high initial total isoflavone concentration It is clear that the concentration can be maintained for a long time.
- Ratio of aglycone contained in the sum of isoflavone and isoflavone aglycone to the amount of aglycone in darcosyl isoflavone (aglycone content in hydarcosyl isoflavone / (aglycone content in isoflavone + isoflavone) Aglycone amount)] was examined from the viewpoint of dissolution stability.
- isoflavone aglycone was added to "Soact W" (isoflavone aglycone 33.
- Example A prepared in Example 1 was used as the enzyme-treated isoflavone.
- composition ratio (Cg) indicates [aglycone content in ⁇ _darcosyl isoflavone / (aglycone content in isoflavone + isoflavone aglycone content)].
- Vitamin C 0.04 g
- Vitamin C 0.04 g
- the product can be suitably used as a fruit juice beverage that does not cause isoflavone precipitation and is suitable for humans who are concerned about osteoporosis.
- This lactic acid beverage can be used as an isoflavone-containing lactic acid beverage that does not precipitate even though the pH is low (acidic).
- Vitamin C 0.04 g
- the present product (jelly) can be used as a clear isoflavone-containing jelly which is not affected by turbidity in spite of being a (semi) solid substance.
- This cream cosmetic has the effect of "preventing skin aging” possessed by isoflavone, and is stable as a tallime.
- composition of the cream by changing the composition of the cream to a lotion, a water-soluble and stable product as a lotion can be obtained.
- FIG. 1 shows a water-soluble isoflavone composition ( ⁇ ), a mixed sample (country) that is a “mixture of a water-soluble isoflavone composition and isoflavone aglycone”, and an isoflavone aglycone ( ⁇ ).
- FIG. 4 is a graph showing the relationship between the time (h) (horizontal axis) elapsed from the start of administration and the total blood isoflavone concentration (nmol / ml) (vertical axis) over time.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Fodder In General (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020057021976A KR101195114B1 (ko) | 2003-05-20 | 2004-05-19 | 수 가용성 이소플라본 조성물 및 그 제조 방법 및 그 용도 |
JP2005506336A JP4982656B2 (ja) | 2003-05-20 | 2004-05-19 | 水可溶性イソフラボン組成物およびその製造方法並びにその用途 |
GB0525944A GB2419095B (en) | 2003-05-20 | 2004-05-19 | Water-soluble isoflavone composition, its preparation and use |
US10/556,879 US7713940B2 (en) | 2003-05-20 | 2004-05-19 | Water-soluble isoflavone composition, process for producing the same, and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003142602 | 2003-05-20 | ||
JP2003-142602 | 2003-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004103380A1 true WO2004103380A1 (ja) | 2004-12-02 |
Family
ID=33475065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/006726 WO2004103380A1 (ja) | 2003-05-20 | 2004-05-19 | 水可溶性イソフラボン組成物およびその製造方法並びにその用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7713940B2 (ja) |
JP (1) | JP4982656B2 (ja) |
KR (1) | KR101195114B1 (ja) |
GB (1) | GB2419095B (ja) |
TW (1) | TWI287985B (ja) |
WO (1) | WO2004103380A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006067874A (ja) * | 2004-09-01 | 2006-03-16 | Sanei Gen Ffi Inc | ペプチド含有飲料 |
JP2010508820A (ja) * | 2006-11-03 | 2010-03-25 | コーン・プロダクツ・インターナショナル・インコーポレイテッド | カプセル化された大豆エキストラクトおよびそれらの製造方法 |
US8658692B2 (en) | 2007-09-05 | 2014-02-25 | Macrocare Tech., Ltd. | Method of preparation an inclusion-complex comprising hydrophobic physiological activation material including with cyclodextrin and its use |
JP2015181399A (ja) * | 2014-03-24 | 2015-10-22 | アサヒ飲料株式会社 | ヘスペリジン含有飲料、苦味改善剤及び苦味改善方法 |
KR20190107690A (ko) * | 2017-01-09 | 2019-09-20 | 에스씨아이팜 에스에이알엘 | 수용성 포스콜린의 신규 제조 방법 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100849145B1 (ko) * | 2006-08-23 | 2008-07-31 | 주식회사 마크로케어 | 사이클로덱스트린을 이용한 제니스테인의 추출방법 |
EP2203074A1 (en) * | 2007-10-18 | 2010-07-07 | Unilever N.V. | Liquid edible composition comprising isoflavones |
KR20190111818A (ko) | 2018-03-23 | 2019-10-02 | 주식회사 오스테온 | 이소플라본의 생체흡수율이 증진된 조성물 |
CN114424823B (zh) * | 2022-01-20 | 2023-07-04 | 江苏海王健康生物科技有限公司 | 一种含天然提取物的降血脂软胶囊及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000078955A (ja) * | 1998-06-23 | 2000-03-21 | Ezaki Glico Co Ltd | 飲食物および薬品 |
JP2000078956A (ja) * | 1998-06-23 | 2000-03-21 | Ezaki Glico Co Ltd | 飲食物および薬品 |
JP2000327692A (ja) * | 1999-05-19 | 2000-11-28 | Ezaki Glico Co Ltd | 新規イソフラボン誘導体 |
JP2002234844A (ja) * | 2000-12-05 | 2002-08-23 | Toyo Seito Kk | 骨密度向上剤およびその利用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4557927A (en) * | 1983-03-10 | 1985-12-10 | Kabushiki Kaisha Hoyashibara | Food products and process for producing same |
JPS59187746A (ja) * | 1983-04-11 | 1984-10-24 | Hayashibara Biochem Lab Inc | 飲食物とその製造方法 |
JPS62126186A (ja) | 1985-11-28 | 1987-06-08 | Tsumura Juntendo Inc | イソフラボン誘導体含有溶液の製造方法 |
US5847108A (en) * | 1996-03-21 | 1998-12-08 | Fujicco Co., Ltd. | Clathrate of isoflavone derivatives and edible composition comprising the same |
JPH09309902A (ja) | 1996-03-21 | 1997-12-02 | Fujitsuko Kk | イソフラボン誘導体の包接物及び該包接物を含む可食性組成物 |
JPH10298175A (ja) | 1997-05-01 | 1998-11-10 | Sunstar Inc | 水易溶性大豆イソフラボンの製造方法 |
JPH11263786A (ja) | 1998-03-17 | 1999-09-28 | Tama Seikagaku Kk | イソフラボン化合物の製造法 |
JP2000327691A (ja) | 1999-05-19 | 2000-11-28 | Ezaki Glico Co Ltd | イソフラボン誘導体ならびに動植物由来の有用成分の製造法 |
JP2002155072A (ja) | 2000-11-16 | 2002-05-28 | Tama Seikagaku Kk | 水溶解性イソフラボン誘導体抽出物の製造方法 |
-
2004
- 2004-05-19 GB GB0525944A patent/GB2419095B/en not_active Expired - Fee Related
- 2004-05-19 WO PCT/JP2004/006726 patent/WO2004103380A1/ja active Application Filing
- 2004-05-19 KR KR1020057021976A patent/KR101195114B1/ko active IP Right Grant
- 2004-05-19 JP JP2005506336A patent/JP4982656B2/ja not_active Expired - Fee Related
- 2004-05-19 US US10/556,879 patent/US7713940B2/en not_active Expired - Fee Related
- 2004-05-20 TW TW093114211A patent/TWI287985B/zh not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000078955A (ja) * | 1998-06-23 | 2000-03-21 | Ezaki Glico Co Ltd | 飲食物および薬品 |
JP2000078956A (ja) * | 1998-06-23 | 2000-03-21 | Ezaki Glico Co Ltd | 飲食物および薬品 |
JP2000327692A (ja) * | 1999-05-19 | 2000-11-28 | Ezaki Glico Co Ltd | 新規イソフラボン誘導体 |
JP2002234844A (ja) * | 2000-12-05 | 2002-08-23 | Toyo Seito Kk | 骨密度向上剤およびその利用 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006067874A (ja) * | 2004-09-01 | 2006-03-16 | Sanei Gen Ffi Inc | ペプチド含有飲料 |
JP4531494B2 (ja) * | 2004-09-01 | 2010-08-25 | 三栄源エフ・エフ・アイ株式会社 | ペプチド含有飲料 |
JP2010508820A (ja) * | 2006-11-03 | 2010-03-25 | コーン・プロダクツ・インターナショナル・インコーポレイテッド | カプセル化された大豆エキストラクトおよびそれらの製造方法 |
US8658692B2 (en) | 2007-09-05 | 2014-02-25 | Macrocare Tech., Ltd. | Method of preparation an inclusion-complex comprising hydrophobic physiological activation material including with cyclodextrin and its use |
JP2015181399A (ja) * | 2014-03-24 | 2015-10-22 | アサヒ飲料株式会社 | ヘスペリジン含有飲料、苦味改善剤及び苦味改善方法 |
KR20190107690A (ko) * | 2017-01-09 | 2019-09-20 | 에스씨아이팜 에스에이알엘 | 수용성 포스콜린의 신규 제조 방법 |
JP2020505339A (ja) * | 2017-01-09 | 2020-02-20 | サイファーム ソシエテ ア レスポンサビリテ リミテSciPharm S.a r.l. | 水溶性フォルスコリンの新規製造法 |
JP7138643B2 (ja) | 2017-01-09 | 2022-09-16 | サイファーム ソシエテ ア レスポンサビリテ リミテ | 水溶性フォルスコリンの新規製造法 |
KR102583356B1 (ko) | 2017-01-09 | 2023-09-26 | 에스씨아이팜 에스에이알엘 | 수용성 포스콜린의 신규 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
GB2419095B (en) | 2008-03-26 |
US20060210607A1 (en) | 2006-09-21 |
KR101195114B1 (ko) | 2012-10-25 |
US7713940B2 (en) | 2010-05-11 |
TW200503687A (en) | 2005-02-01 |
GB2419095A (en) | 2006-04-19 |
GB0525944D0 (en) | 2006-02-01 |
JP4982656B2 (ja) | 2012-07-25 |
KR20060033719A (ko) | 2006-04-19 |
TWI287985B (en) | 2007-10-11 |
JPWO2004103380A1 (ja) | 2006-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3134233B2 (ja) | α−グリコシル ケルセチンとその製造方法並びに用途 | |
JP3060227B2 (ja) | α―グリコシル ヘスペリジンとその製造方法並びに用途 | |
EP3351258B1 (en) | A method for producing an equol- and ornithine-containing fermented soybean hypocotyl material | |
KR0162495B1 (ko) | 알파-글리코실-l-아스코르브산 및 그 제조방법 | |
TWI242437B (en) | Composition for reducing low density lipoprotein cholesterol concentration | |
EP3453766B1 (en) | Method for producing flavonoid inclusion compounds | |
CN107249356A (zh) | 用于口服摄入或使用的甜菊醇糖苷化合物、组合物以及用于增强甜菊醇糖苷溶解度的方法 | |
JP2010143930A (ja) | 鏡像異性のエクオールを含有する組成物および製品、およびその製造方法 | |
JP2006182777A (ja) | へスペレチン包接化合物およびナリンゲニン包接化合物の合成方法 | |
KR19990014205A (ko) | 플라보노이드 및 파피아 가공물을 함유한 조성물 | |
KR100203759B1 (ko) | 신규의 알파-글리코실 나린진 및 그 제조방법과 용도 | |
KR20140072307A (ko) | 사이클로덱스트린을 포함하는 카테킨 생체 이용률 증진제 | |
JP5226297B2 (ja) | 8−ヒドロキシリクイリチゲニン及び3’−ヒドロキシイソリクイリチゲニンの少なくともいずれかの製造方法 | |
KR101119311B1 (ko) | 감귤과피로부터 분리된 헤스페리딘의 정제방법 | |
JP4982656B2 (ja) | 水可溶性イソフラボン組成物およびその製造方法並びにその用途 | |
JP4846141B2 (ja) | 即効性および持続性を有するフラボノイド配糖体を含有する経口栄養補給剤 | |
JP3549436B2 (ja) | α−グリコシルヘスペリジンとその製造方法並びに用途 | |
KR20130014192A (ko) | 루부소사이드 생산하는 신규 제조방법 | |
JP4051482B2 (ja) | α−グリコシルヘスペリジンを含んでなる医薬組成物 | |
JPH0358790A (ja) | α―グリコシルルチンの製造法とその用途 | |
KR100227598B1 (ko) | 신규의α-글리코실나린진을함유시킨화장품 | |
JP2023177322A (ja) | 新規なアスペルギルス・オリーゼ菌株及びその用途 | |
JP2000327576A (ja) | 4G−α−D−グルコピラノシルルチンを含有せしめた抗感受性疾患剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005506336 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10556879 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057021976 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0525944.5 Country of ref document: GB Ref document number: 0525944 Country of ref document: GB |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057021976 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10556879 Country of ref document: US |